Difference between revisions of "NextGen-O2k Exploitation"
From Bioblast
Tindle Lisa (talk | contribs) |
Tindle Lisa (talk | contribs) |
||
Line 19: | Line 19: | ||
::::'''Project Year 1:''' During the first year of the project we dedicated time to our IP strategy and successfully registered “NextGen-O2k”, “DatLab” and “High-Resolution Respirometry” as EU-trademarks. In addition to IP management and periodic IP Watch to ensure that our Freedom-to-operate (FTO) remains unimpeded, we also increased our distributor engagement. Furthermore, we explored the NextGen-O2k’s potential as a medical device and made progress on its algal biotechnology applications. The final component of WP4 for year one was the preparation for ISO certification and the implementation of new quality control measures. | ::::'''Project Year 1:''' During the first year of the project we dedicated time to our IP strategy and successfully registered “NextGen-O2k”, “DatLab” and “High-Resolution Respirometry” as EU-trademarks. In addition to IP management and periodic IP Watch to ensure that our Freedom-to-operate (FTO) remains unimpeded, we also increased our distributor engagement. Furthermore, we explored the NextGen-O2k’s potential as a medical device and made progress on its algal biotechnology applications. The final component of WP4 for year one was the preparation for ISO certification and the implementation of new quality control measures. | ||
::::'''Project Year 2:''' Year 2 was focused on ensuring processes were in place to deliver high quality and customer satisfaction. This included creating a quality policy statement as well as carrying out a customer satisfaction survey. Our Distributor Relations Dragon, Feiyuan Zhang, continued to work closely with our distributors keeping them abreast of progress and gaining valuable feedback. | |||
== Progress and next steps == | == Progress and next steps == | ||
See » [[Talk:NextGen-O2k Exploitation|Track record]] | |||
<br/> | <br/> | ||
<gallery mode=default perrow=4 widths="350px" heights="300px"> | <gallery mode=default perrow=4 widths="350px" heights="300px"> | ||
File: | File:Analytica China 2020 2.jpg|The [[CN Beijing Huawei]] team representing Oroboros Instruments at the [[Analytica China 2020 Shanghai CN|Analytica China 2020 Event]] November 2020 | ||
File:JP Onsite.jpg| | File:Timi in Linz Aug 2020.jpg|[[Komlodi Timea|Timea Komlodi, PhD.]] at an on-site visit in Linz August 2020 | ||
File: | |||
File:ASMRM & J-mit 2019 Fukuoka JP.jpeg|The Oroboros booth at the ASMRM & J-mit 2019 | File:JP Onsite.jpg|[[Cardoso Luiza HD|Luiza Cardoza, PhD.]] at an on-site visit in Japan February 2020 | ||
File:ASMRM2021.JPG|Snapshot of the [[ASMRM & J-mit 2019 Fukuoka JP|J-Mit and ASMRM 2019]] | |||
File:ASMRM & J-mit 2019 Fukuoka JP.jpeg|The Oroboros booth at the [[ASMRM & J-mit 2019 Fukuoka JP|ASMRM & J-mit October 2019]] | |||
File:ORODM1A.jpg|The first [[OroDM01 Innsbruck AT|Distributor Meeting]] July 2019 | |||
|- | |- | ||
</gallery> | </gallery> |
Revision as of 10:42, 6 May 2021
Template:MitoFit highlights page name
The revolutionary all-in-one instrument to conquer mitochondrial disease.
WP4: Exploitation
Abstract
- Preparation for a successful market launch of the NextGen-O2k.
Achievements
- Project Year 1: During the first year of the project we dedicated time to our IP strategy and successfully registered “NextGen-O2k”, “DatLab” and “High-Resolution Respirometry” as EU-trademarks. In addition to IP management and periodic IP Watch to ensure that our Freedom-to-operate (FTO) remains unimpeded, we also increased our distributor engagement. Furthermore, we explored the NextGen-O2k’s potential as a medical device and made progress on its algal biotechnology applications. The final component of WP4 for year one was the preparation for ISO certification and the implementation of new quality control measures.
- Project Year 2: Year 2 was focused on ensuring processes were in place to deliver high quality and customer satisfaction. This included creating a quality policy statement as well as carrying out a customer satisfaction survey. Our Distributor Relations Dragon, Feiyuan Zhang, continued to work closely with our distributors keeping them abreast of progress and gaining valuable feedback.
Progress and next steps
See » Track record
The CN Beijing Huawei team representing Oroboros Instruments at the Analytica China 2020 Event November 2020
Timea Komlodi, PhD. at an on-site visit in Linz August 2020
Luiza Cardoza, PhD. at an on-site visit in Japan February 2020
Snapshot of the J-Mit and ASMRM 2019
The Oroboros booth at the ASMRM & J-mit October 2019
The first Distributor Meeting July 2019